This week, AstraZeneca shared positive topline results from its trial evaluating its breast cancer ADC, datopotamab deruxtecan (Dato-DXd).
According to the statement shared, the trials showed that the drug significantly improved progression-free survival compared to chemotherapy in patients with HR positive, HER2 low or negative breast cancer.
Developed with Daiichi Sankyo, Dato-DXd is a TROP2-directed DXd ADC, designed to target a protein called TROP2 found in cancer cells. Dato-DXd is made up of an antibody that recognizes TROP2 and a medication that can kill cancer cells attached to it.
The companies have several ongoing trials for the ADC. In their TROPION-Breast02 trial, the drug is being compared to chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer who are ineligible for anti-PDL1 therapy. Meanwhile, in TROPION-Breast03, Dato-DXd is being evaluated in combination with or without durvalumab, as compared to the first in line therapies for patients with stage I-III TNBC who still have residual disease after neoadjuvant therapy.
Just a few weeks ago, the companies shared positive data from its global, randomized, multicenter, open-label phase 3 trial, TROPION-Lung01, evaluating Dato-DXd for safety and efficacy in approximately 600 patients with locally advanced or metastatic NSCLC.
The partners said plans for global regulatory submissions are underway.
